GSK plc, a leading pharmaceutical company, has announced promising results from its phase 3 trials, ANCHOR-1 and ANCHOR-2, evaluating the effectiveness and safety of depemokimab for treating chronic rhinosinusitis with nasal polyps (CRSwNP). This chronic condition affects approximately 4% of the population, with a significant portion experiencing uncontrolled symptoms.
The trials assessed depemokimab against a placebo in adults with CRSwNP. Both studies successfully met their primary endpoints, showing a substantial reduction in nasal polyp size and improvement in nasal obstruction after 52 weeks of treatment. The severity and incidence of adverse events were similar between patients receiving depemokimab and those on placebo, suggesting a favorable safety profile.
These positive findings provide compelling evidence for depemokimab’s potential as a new treatment option for CRSwNP. The drug effectively targets type 2 inflammation, a key contributor to nasal polyp growth and obstruction. This is significant because many CRSwNP patients rely heavily on corticosteroids, often experiencing recurrence of polyps after surgery.
Depemokimab is an ultra-long-acting biologic administered once every six months. Its efficacy in these trials, coupled with its convenient dosing regimen, suggests a potentially significant improvement in the management of CRSwNP for patients.
Further analysis of the data is ongoing, and the full results of ANCHOR-1 and ANCHOR-2 will be presented at an upcoming scientific congress. GSK is also planning regulatory filings based on these data, along with results from its SWIFT-1 and SWIFT-2 trials investigating depemokimab’s effectiveness in treating severe asthma.
The positive results from these trials demonstrate the potential of depemokimab to offer a targeted and sustained solution for millions of people suffering from uncontrolled CRSwNP. As GSK moves forward with regulatory submissions, the hope is that depemokimab will soon become a valuable treatment option for patients struggling with this debilitating condition.